Upgrade to Finviz Elite: Get our fastest platform speed, real-time data, and unlimited screening & charting. Start Free Trial

PFSA

Profusa Inc

Feb 13 • 04:00PM ET

2.01

-1.01 -33.44 %

Healthcare • Medical Devices • USA • NASD

Feb 13, 8:30 PMS-1 filing for large equity offering sparked dilution fears driving 33.44% plunge.

Held by: VXF

Scroll to Statements

Index	-	P/E	-	EPS (ttm)	-283.72	Insider Own	5.20%	Shs Outstand	1.23M	Perf Week	-54.03%
Market Cap	2.48M	Forward P/E	-	EPS next Y	-	Insider Trans	0.00%	Shs Float	1.17M	Perf Month	-70.29%
Enterprise Value	19.57M	PEG	-	EPS next Q	-	Inst Own	5.23%	Short Float	5.20%	Perf Quarter	-86.80%
Income	-39.09M	P/S	-	EPS this Y	-	Inst Trans	7.55%	Short Ratio	0.17	Perf Half Y	-95.06%
Sales	0.00M	P/B	-	EPS next Y	-	ROA	-599.88%	Short Interest	0.06M	Perf YTD	-74.43%
Book/sh	-61.03	P/C	0.62	EPS next 5Y	-	ROE	-1484.67%	52W High	957.00 -99.79%	Perf Year	-99.77%
Cash/sh	3.23	P/FCF	-	EPS past 3/5Y	- -	ROIC	-	52W Low	2.80 -28.21%	Perf 3Y	-99.74%
Dividend Est.	-	EV/EBITDA	-	Sales past 3/5Y	- -	Gross Margin	-	Volatility	26.79% 20.11%	Perf 5Y	-
Dividend TTM	-	EV/Sales	-	EPS Y/Y TTM	-2290.92%	Oper. Margin	-	ATR (14)	1.15	Perf 10Y	-
Dividend Ex-Date	-	Quick Ratio	0.18	Sales Y/Y TTM	-	Profit Margin	-	RSI (14)	25.57	Recom	-
Dividend Gr. 3/5Y	- -	Current Ratio	0.18	EPS Q/Q	-4650.10%	SMA20	-66.36%	Beta	-	Target Price	-
Payout	-	Debt/Eq	-	Sales Q/Q	-	SMA50	-73.96%	Rel Volume	1.52	Prev Close	3.02
Employees	2	LT Debt/Eq	-	Earnings	-	SMA200	-99.14%	Avg Volume	364.71K	Price	2.01
IPO	Jan 24, 2022	Option/Short	No / Yes	EPS/Sales Surpr.	- -	Trades		Volume	555,768	Change	-33.44%

Feb-13-26 08:30AM	Profusa and Mayo Clinic collaborate to Advance High-Impact Clinical Applications of Oxygen Monitoring Technologies (GlobeNewswire) -33.44%
Feb-12-26 04:30PM	Profusa and Mayo Clinic collaborate to Advance High-Impact Clinical Applications of Oxygen Monitoring Technologies (GlobeNewswire)
Feb-05-26 08:00AM	Profusa Announces 1-for-75 Reverse Stock Split (GlobeNewswire) -36.35%
Jan-29-26 08:00AM	Profusa Presents Positive US-Study Clinical Results at Leipzig Interventional Course (LINC) 2026 (GlobeNewswire)
Jan-16-26 12:51PM	Profusa Stock Spikes As Lumee System Targets Research Market (Benzinga)
07:30AM	Loading…
07:30AM	Profusa Launches Lumee Tissue Oxygen Healthcare Research Offerings, Initiating First Commercial Revenue (GlobeNewswire)
Jan-08-26 07:30AM	Profusa Adds Leading Greek Vascular Surgeon to Customer Base (GlobeNewswire)
Dec-31-25 07:30AM	Profusa Bolsters European Commercial Network with New French Distributor, MedSell (GlobeNewswire) -13.96%
Dec-30-25 07:30AM	Profusa Restructures Senior Secured Convertible Notes, Only Convertible Above $0.35 (GlobeNewswire) +78.33%
Dec-15-25 07:30AM	Profusa U.S. Study Met Primary End Points as Presented at Late Breaking Clinical Trials at Paris Vascular Insights 2025 (GlobeNewswire) -19.87%
Dec-11-25 08:30AM	Profusa to Present US-Study Clinical Data at Leipzig Interventional Course (LINC) 2026 (GlobeNewswire)
Nov-24-25 08:15AM	Profusa to Present Late Breaking U.S.-Based Clinical Trial Update at Paris Vascular Insights 2025 (GlobeNewswire) +8.38%
Nov-19-25 05:44PM	Profusa Announces Third Quarter Business and Financial Highlights (GlobeNewswire) -5.95% -19.59%
Oct-30-25 07:30AM	Profusa Outlines Potential Path to $250 Million Revenue by 2030, Driven by Sequential Lumee Oxygen and Glucose Monitoring Launches (GlobeNewswire) -9.85%
Oct-28-25 08:30AM	Profusa Completes Manufacturing Build-Out, On Track to Begin Product Shipments and Revenue in Early 2026 (GlobeNewswire)
08:30AM	Loading…
Oct-22-25 08:30AM	Profusa Expands Sales Footprint with New Distributor for Lumee Oxygen Platform in Europe (GlobeNewswire) -8.11%
Oct-15-25 08:30AM	Profusa Expands Sales Footprint with New Distributor for Lumee Oxygen Platform in Europe (GlobeNewswire)
Oct-07-25 08:15AM	Profusa Invests Additional $1 Million in Digital Treasury Assets (GlobeNewswire)
Oct-01-25 08:30AM	Profusa Adds a Leading French Critical Limb Ischemia Surgeon to Customer Base (GlobeNewswire)
Sep-11-25 08:45AM	Report Highlights Growth in AI Biomarker Monitoring as Industry Giant's GPUs Power Next-Gen Platform (PR Newswire) +74.04%
08:30AM	Profusa Adopts NVIDIA-Powered Technology to Build AI-Driven Insight Portal for Continuous Biomarker Monitoring (GlobeNewswire)
Sep-04-25 08:30AM	Profusa Adds Head of Vascular Surgery Department at AZ Sint Blasius Hospital, Belgium to Growing Customer Base (GlobeNewswire) -7.94%
Sep-02-25 04:05PM	Profusa to Present at the H.C. Wainwright 27th Annual Global Investment Conference (GlobeNewswire) -7.83% -5.00%
Aug-27-25 08:45AM	Profusa Announces Commercial and Clinical Collaboration with Head of Angiography, Medical University of Graz, Austria (GlobeNewswire)
Aug-19-25 08:15AM	Profusa Welcomes Former Acting U.S. Veterans Affairs Secretary Peter O'Rourke as Lead Independent Director; Adds Seasoned Finance Executive Fred Knechtel as CFO (GlobeNewswire) -7.99%
Aug-06-25 08:15AM	Profusa, Inc. Provides Strategy Overview and Business Update for Investors (GlobeNewswire) -7.72%
Jul-31-25 08:15AM	Profusa Secures Lumee Oxygen Platform Distributor in Spain (GlobeNewswire)
Jul-30-25 08:00AM	Profusa Announces Initial $1 Million Bitcoin Investment to Initiate Its Digital Asset Treasury Strategy (GlobeNewswire) -17.80%
Jul-21-25 08:00AM	Profusa Announces $100 Million Equity Line of Credit to Initiate Bitcoin Treasury Strategy (GlobeNewswire) -17.32%
Jul-11-25 04:00PM	Profusa Announces Closing of Business Combination and the Commencement of Trading on Nasdaq (GlobeNewswire) -80.02% -19.20%

Profusa, Inc. engages in the biofeedback for chronic disease management and healthy living services. The company is headquartered in Berkeley, CA.

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

PFSA

Profusa Inc

Upgrade your FINVIZ experience